{"entity":{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","aka":[],"tldr":"Founded the German Breast Group and led KATHERINE, which made T-DM1 standard after residual disease.","summary":"Gunter von Minckwitz is the founder and former Chair of the German Breast Group (GBG). His specialisms are breast cancer, neoadjuvant chemotherapy and residual disease. He led the GeparTrio and GeparQuinto neoadjuvant trials and was principal investigator of KATHERINE, the trial of adjuvant trastuzumab emtansine for patients with residual invasive HER2-positive breast cancer after neoadjuvant therapy, reported in the New England Journal of Medicine. KATHERINE made T-DM1 the standard after residual disease. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Minckwitz%20G%5BAuthor%5D%20KATHERINE"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-emtansine"],"companies":["gbg"],"institutions":[],"pathways":[],"terms":[],"trials":["katherine"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder and former Chair, German Breast Group","institutionId":"gbg","specialisms":["Breast cancer","Neoadjuvant chemotherapy","Residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Minckwitz%20G%5BAuthor%5D%20KATHERINE"}],"papers":[{"title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1814017"}]},"route":"/people/gunter-von-minckwitz/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"company":[{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/"}],"trial":[{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/"},{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/"}],"paper":[{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/"},{"id":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","kind":"paper","name":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","route":"/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}]}}